Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab followed by alendronate for osteogenesis imperfecta with osteoporosis
jRCTs031220726Recruiting
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of romosozumab and alendronate in osteogenesis imperfecta (OI) and osteoporosis. Primary endpoint: Primary: Percentage change in lumbar spine bone mineral density during romosozumab treatment. Started Mar 2023; status: recruiting.
02
Drugs
romosozumabalendronate
03
Conditions
osteogenesis imperfecta (OI)osteoporosis
Beyond the preview
Go deeper on jRCTs031220726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220726.